Is Juno Therapeutics Stock Still a Strong Buy?
Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from two different catalysts during the month.
First off, the company provided yet another positive clinical update for its lead cell therapy, JCAR017, in relapsed and refractory aggressive B cell non-Hodgkin lymphoma (NHL) at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.
Image source: Getty Images.
Source: Fool.com
Novartis AG ADR Aktie
136,00 €
-1,45 %
Durchaus positiv bewertet unsere Community derzeit Novartis AG ADR mit 11 Buy-Einschätzungen und 1 Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Novartis AG ADR mit einem Kursziel von 150 € im Vergleich zu 136.0 €.
